170 related articles for article (PubMed ID: 23637780)
1. Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta.
Bustamante MF; Nurtdinov RN; Río J; Montalban X; Comabella M
PLoS One; 2013; 8(4):e60994. PubMed ID: 23637780
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of responders to interferon therapy for relapsing MS.
Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
[TBL] [Abstract][Full Text] [Related]
3. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.
Comabella M; Lünemann JD; Río J; Sánchez A; López C; Julià E; Fernández M; Nonell L; Camiña-Tato M; Deisenhammer F; Caballero E; Tortola MT; Prinz M; Montalban X; Martin R
Brain; 2009 Dec; 132(Pt 12):3353-65. PubMed ID: 19741051
[TBL] [Abstract][Full Text] [Related]
4. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
[TBL] [Abstract][Full Text] [Related]
5. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
7. Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.
Oturai DB; Søndergaard HB; Börnsen L; Sellebjerg F; Christensen JR
Scand J Immunol; 2016 Jan; 83(1):72-80. PubMed ID: 26395032
[TBL] [Abstract][Full Text] [Related]
8. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.
Bustamante MF; Fissolo N; Río J; Espejo C; Costa C; Mansilla MJ; Lizasoain I; Moro MA; Carmen Edo M; Montalban X; Comabella M
Ann Neurol; 2011 Oct; 70(4):634-45. PubMed ID: 22028223
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort.
Pereira VC; Malfetano FR; Meira ID; Souza LF; Liem AM; Maiolino A; Alves-Leon SV
Arq Neuropsiquiatr; 2012 Oct; 70(10):774-9. PubMed ID: 23060103
[TBL] [Abstract][Full Text] [Related]
10. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis.
Prosperini L; Gallo V; Petsas N; Borriello G; Pozzilli C
Eur J Neurol; 2009 Nov; 16(11):1202-9. PubMed ID: 19538207
[TBL] [Abstract][Full Text] [Related]
11. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
12. Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
Aliaga-Gaspar P; Hurtado-Guerrero I; Ciano-Petersen NL; Urbaneja P; Brichette-Mieg I; Reyes V; Rodriguez-Bada JL; Alvarez-Lafuente R; Arroyo R; Quintana E; Ramió-Torrentà L; Alonso A; Leyva L; Fernández O; Oliver-Martos B
Front Immunol; 2021; 12():778204. PubMed ID: 34975865
[TBL] [Abstract][Full Text] [Related]
13. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns.
O'Rourke KE; Hutchinson M
Mult Scler; 2005 Feb; 11(1):46-50. PubMed ID: 15732266
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients.
Hecker M; Thamilarasan M; Koczan D; Schröder I; Flechtner K; Freiesleben S; Füllen G; Thiesen HJ; Zettl UK
Int J Mol Sci; 2013 Aug; 14(8):16087-110. PubMed ID: 23921681
[TBL] [Abstract][Full Text] [Related]
16. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
Prosperini L; Borriello G; De Giglio L; Leonardi L; Barletta V; Pozzilli C
BMC Neurol; 2011 Feb; 11():26. PubMed ID: 21352517
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
19. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA
Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319
[TBL] [Abstract][Full Text] [Related]
20. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.
Somani AK; Swick AR; Cooper KD; McCormick TS
Arch Dermatol; 2008 Oct; 144(10):1341-9. PubMed ID: 18936398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
